Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules

Published:2014-03 Issue:3 Volume:191 Page:611-618
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Atkinson Bradley J.¹,Kalra Sarathi²,Wang Xuemei³,Bathala Tharakeswara⁴,Corn Paul²,Tannir Nizar M.²,Jonasch Eric²

Affiliation:

1. Department of Pharmacy Clinical Programs, University of Texas M.D. Anderson Cancer Center, Houston, Texas

2. Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

3. Division of Quantitative Sciences, University of Texas M.D. Anderson Cancer Center, Houston, Texas

4. Division of Radiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference23 articles.

1. Sutent® (sunitinib) package insert,2012

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

3. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis;Houk;Cancer Chemother Pharmacol,2010

4. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer;Faivre;J Clin Oncol,2006

5. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma;Escudier;J Clin Oncol,2009

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?;Expert Review of Anticancer Therapy;2023-04-10

2. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring;Biological and Pharmaceutical Bulletin;2022-07-01

3. Efficacy of the 1<sup>st</sup> generation tyrosine kinase inhibitor sunitinib in the treatment of metastatic renal cell carcinoma in alternative dosing regimens;Meditsinskiy sovet = Medical Council;2022-06-18

4. Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting;Frontiers in Oncology;2022-06-08

5. Developments in personalized therapy for metastatic renal cell carcinoma;Expert Review of Anticancer Therapy;2022-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3